An update on immunotherapy in uro-oncology
2021-01-01 Cimadamore, A.; Rizzo, A.; Mollica, V.; Massari, F.; Lopez-Beltran, A.; Scarpelli, M.; Cheng, L.; Santoni, M.; Montironi, R.
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype
2019-01-01 Rebola, J.; Aguiar, P.; Blanca, A.; Montironi, R.; Cimadamore, A.; Cheng, L.; Henriques, V.; Lobato-Faria, P.; Lopez-Beltran, A.
Agent-Based Learning Model for the Obesity Paradox in RCC
2021-01-01 Belenchia, M.; Rocchetti, G.; Maestri, S.; Cimadamore, A.; Montironi, R.; Santoni, M.; Merelli, E.
Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871
2020-01-01 Cimadamore, A.; Scarpelli, M.; Cheng, L.; Lopez-Beltran, A.; Galosi, A. B.; Montorsi, F.; Montironi, R.
Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view
2020-01-01 Cimadamore, A.; Scarpelli, M.; Massari, F.; Eckstein, M.; Gevaert, T.; Cheng, L.; Lopez-Beltran, A.; Montironi, R.
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation
2021-01-01 Cimadamore, A.; Mazzucchelli, R.; Lopez-Beltran, A.; Massari, F.; Santoni, M.; Scarpelli, M.; Cheng, L.; Montironi, R.
Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?
2019-01-01 Montironi, R.; Cheng, L.; Cimadamore, A.; Lopez-Beltran, A.
Pathology and molecular updates in tumors of the prostate: towards a personalized approach
2017-01-01 Gasparrini, Silvia; Cimadamore, Alessia; Mazzucchelli, Roberta; Scarpelli, Marina; Massari, F; Raspollini, Mr; Galosi, Andrea Benedetto; Lopez Beltran, A; Cheng, L; Montironi, Rodolfo
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion
2019-01-01 Cimadamore, A.; Scarpelli, M.; Cheng, L.; Lopez-Beltran, A.; Montironi, R.
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review
2021-01-01 Rizzo, A.; Mollica, V.; Cimadamore, A.; Santoni, M.; Scarpelli, M.; Schiavina, R.; Cheng, L.; Lopez-Beltran, A.; Brunocilla, E.; Montironi, R.; Massari, F.
Tivozanib for the treatment of renal cell carcinoma
2018-01-01 Santoni, Matteo; Massari, Francesco; Piva, Francesco; Carrozza, Francesco; Di Nunno, Vincenzo; Cimadamore, Alessia; Martignetti, Angelo; Montironi, Rodolfo; Battelli, Nicola
Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27–30: Morphologic Documentation from Didactic Cases of Large-format Histology
2020-01-01 Cimadamore, A.; Scarpelli, M.; Cheng, L.; Lopez-Beltran, A.; Montorsi, F.; Montironi, R.
Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers
2018-01-01 Montironi, R.; Cimadamore, A.; Cheng, L.; Lopez-Beltran, A.; Scarpelli, M.
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice
2018-01-01 Chovanec, M.; Albany, C.; Mego, M.; Montironi, R.; Cimadamore, A.; Cheng, L.
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy?
2020-01-01 Paner, G. P.; Cimadamore, A.; Darrell, C. M.; Tretiakova, M. S.; Montironi, R.
Molecular diagnostics in uro-oncology
2020-01-01 Montironi, R.; Cheng, L.; Cimadamore, A.; Lopez-Beltran, A.
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology
2020-01-01 Rolim, I.; Henriques, V.; Rolim, N.; Blanca, A.; Marques, R. C.; Volavsek, M.; Carvalho, I.; Montironi, R.; Cimadamore, A.; Raspollini, M. R.; Cheng, L.; Lopez-Beltran, A.
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
2021-01-01 Santoni, Matteo; Massari, Francesco; Bracarda, Sergio; Procopio, Giuseppe; Milella, Michele; De Giorgi, Ugo; Basso, Umberto; Aurilio, Gaetano; Incorvaia, Lorena; Martignetti, Angelo; Rizzo, Mimma; Cartenì, Giacomo; Grande, Enrique; Matrana, Marc R.; Crabb, Simon; Vau, Nuno; Sorgentoni, Giulia; Cimadamore, Alessia; Montironi, Rodolfo; Battelli, Nicola
Are liver nested stromal epithelial tumors always low aggressive?
2017-01-01 Meletani, T; Cantini, L; Lanese, A; Nicolini, D; Cimadamore, A; Agostini, A; Ricci, Giulia; Antognoli, S; Mandolesi, A; Cortelazzo, GUIDO MARIA; Alaggio, R; Giuseppetti, Gm; Scarpelli, M; Vivarelli, M; Berardi, R.
Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer
2019-01-01 Mollica, Veronica; Di Nunno, Vincenzo; Cimadamore, Alessia; Lopez-Beltran, Antonio; Cheng, Liang; Santoni, Matteo; Scarpelli, Marina; Montironi, Rodolfo; Massari, Francesco
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| An update on immunotherapy in uro-oncology | 1-gen-2021 | Cimadamore, A.; Rizzo, A.; Mollica, V.; Massari, F.; Lopez-Beltran, A.; Scarpelli, M.; Cheng, L.; Santoni, M.; Montironi, R. | |
| Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype | 1-gen-2019 | Rebola, J.; Aguiar, P.; Blanca, A.; Montironi, R.; Cimadamore, A.; Cheng, L.; Henriques, V.; Lobato-Faria, P.; Lopez-Beltran, A. | |
| Agent-Based Learning Model for the Obesity Paradox in RCC | 1-gen-2021 | Belenchia, M.; Rocchetti, G.; Maestri, S.; Cimadamore, A.; Montironi, R.; Santoni, M.; Merelli, E. | |
| Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871 | 1-gen-2020 | Cimadamore, A.; Scarpelli, M.; Cheng, L.; Lopez-Beltran, A.; Galosi, A. B.; Montorsi, F.; Montironi, R. | |
| Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view | 1-gen-2020 | Cimadamore, A.; Scarpelli, M.; Massari, F.; Eckstein, M.; Gevaert, T.; Cheng, L.; Lopez-Beltran, A.; Montironi, R. | |
| Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation | 1-gen-2021 | Cimadamore, A.; Mazzucchelli, R.; Lopez-Beltran, A.; Massari, F.; Santoni, M.; Scarpelli, M.; Cheng, L.; Montironi, R. | |
| Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2? | 1-gen-2019 | Montironi, R.; Cheng, L.; Cimadamore, A.; Lopez-Beltran, A. | |
| Pathology and molecular updates in tumors of the prostate: towards a personalized approach | 1-gen-2017 | Gasparrini, Silvia; Cimadamore, Alessia; Mazzucchelli, Roberta; Scarpelli, Marina; Massari, F; Raspollini, Mr; Galosi, Andrea Benedetto; Lopez Beltran, A; Cheng, L; Montironi, Rodolfo | |
| Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion | 1-gen-2019 | Cimadamore, A.; Scarpelli, M.; Cheng, L.; Lopez-Beltran, A.; Montironi, R. | |
| TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review | 1-gen-2021 | Rizzo, A.; Mollica, V.; Cimadamore, A.; Santoni, M.; Scarpelli, M.; Schiavina, R.; Cheng, L.; Lopez-Beltran, A.; Brunocilla, E.; Montironi, R.; Massari, F. | |
| Tivozanib for the treatment of renal cell carcinoma | 1-gen-2018 | Santoni, Matteo; Massari, Francesco; Piva, Francesco; Carrozza, Francesco; Di Nunno, Vincenzo; Cimadamore, Alessia; Martignetti, Angelo; Montironi, Rodolfo; Battelli, Nicola | |
| Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27–30: Morphologic Documentation from Didactic Cases of Large-format Histology | 1-gen-2020 | Cimadamore, A.; Scarpelli, M.; Cheng, L.; Lopez-Beltran, A.; Montorsi, F.; Montironi, R. | |
| Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers | 1-gen-2018 | Montironi, R.; Cimadamore, A.; Cheng, L.; Lopez-Beltran, A.; Scarpelli, M. | |
| Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice | 1-gen-2018 | Chovanec, M.; Albany, C.; Mego, M.; Montironi, R.; Cimadamore, A.; Cheng, L. | |
| Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? | 1-gen-2020 | Paner, G. P.; Cimadamore, A.; Darrell, C. M.; Tretiakova, M. S.; Montironi, R. | |
| Molecular diagnostics in uro-oncology | 1-gen-2020 | Montironi, R.; Cheng, L.; Cimadamore, A.; Lopez-Beltran, A. | |
| Clinicopathologic analysis of upper urinary tract carcinoma with variant histology | 1-gen-2020 | Rolim, I.; Henriques, V.; Rolim, N.; Blanca, A.; Marques, R. C.; Volavsek, M.; Carvalho, I.; Montironi, R.; Cimadamore, A.; Raspollini, M. R.; Cheng, L.; Lopez-Beltran, A. | |
| Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? | 1-gen-2021 | Santoni, Matteo; Massari, Francesco; Bracarda, Sergio; Procopio, Giuseppe; Milella, Michele; De Giorgi, Ugo; Basso, Umberto; Aurilio, Gaetano; Incorvaia, Lorena; Martignetti, Angelo; Rizzo, Mimma; Cartenì, Giacomo; Grande, Enrique; Matrana, Marc R.; Crabb, Simon; Vau, Nuno; Sorgentoni, Giulia; Cimadamore, Alessia; Montironi, Rodolfo; Battelli, Nicola | |
| Are liver nested stromal epithelial tumors always low aggressive? | 1-gen-2017 | Meletani, T; Cantini, L; Lanese, A; Nicolini, D; Cimadamore, A; Agostini, A; Ricci, Giulia; Antognoli, S; Mandolesi, A; Cortelazzo, GUIDO MARIA; Alaggio, R; Giuseppetti, Gm; Scarpelli, M; Vivarelli, M; Berardi, R. | |
| Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer | 1-gen-2019 | Mollica, Veronica; Di Nunno, Vincenzo; Cimadamore, Alessia; Lopez-Beltran, Antonio; Cheng, Liang; Santoni, Matteo; Scarpelli, Marina; Montironi, Rodolfo; Massari, Francesco |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista47361
- 2 Contributo in Volume1
- 3 Libro1
Data di pubblicazione
- In corso di stampa37
- 2020 - 202713529
- 2010 - 201915290
- 2000 - 200910529
- 1990 - 19995844
- 1980 - 19891783
- 1970 - 1979315
- 1960 - 196935
Editore
- Elsevier BV:PO Box 211, 1000 AE A...288
- American Institute of Physics:2 H...269
- Germany: Springer Verlag Germany101
- Elsevier Science Limited:Oxford F...71
- Elsevier Science Incorporated / N...60
- Springer Verlag Germany:Tiergarte...57
- Taylor & Francis Limited:Rankine ...56
- Edizioni Minerva Medica:Corso Bra...52
- S Karger AG:Allschwilerstrasse 10...48
- Annals Publishing Company:4507 La...47
Rivista
- PHYSICAL REVIEW LETTERS520
- PHYSICS LETTERS. SECTION B491
- THE EUROPEAN PHYSICAL JOURNAL. C,...451
- JOURNAL OF HIGH ENERGY PHYSICS351
- PHYSICAL REVIEW D, PARTICLES, FIE...305
- NUCLEAR INSTRUMENTS & METHODS IN ...202
- PHYSICAL REVIEW D157
- THE ASTROPHYSICAL JOURNAL156
- PLOS ONE149
- SCIENTIFIC REPORTS133
Serie
- REGIONAL DOSSIERS SERIES1
Keyword
- Humans1080
- Female609
- Male544
- Middle Aged356
- Italy330
- Adult316
- COVID-19313
- Medicine (all)282
- Aged281
- Biochemistry192
Lingua
- eng30123
- ita9631
- fre359
- spa205
- ger192
- rus48
- fur28
- und27
- lat25
- pol25
Accesso al fulltext
- no fulltext32299
- open8479
- reserved6158
- partially open395
- restricted18
- embargoed10
- mixed3